CARGO Therapeutics (CRGX) Provides Corporate Update

Go back to CARGO Therapeutics (CRGX) Provides Corporate Update

CARGO Therapeutics Provides Corporate Update

March 18, 2025 4:05 PM EDT

- Development of CRG-023 and allogeneic platform suspended; further reduction in force (RIF) of approximately 90% to preserve cash and maximize shareholder value -

- CARGO had cash, cash equivalents and marketable securities of $368.1 million as of December 31, 2024 -

- Anup Radhakrishnan appointed as interim CEO to pursue reverse merger or other business combination -

SAN CARLOS, Calif., March 18, 2025 (GLOBE NEWSWIRE) --... More